{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:20:08Z","timestamp":1792448408891,"version":"4.5.0"},"reference-count":138,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0054577"],"award-info":[{"award-number":["NNF19OC0054577"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["9039-00039B"],"award-info":[{"award-number":["9039-00039B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Oral administration of a combination of two or three antiretroviral drugs (cART) has transformed HIV from a life-threatening disease to a manageable infection. However, as the discontinuation of therapy leads to virus rebound in plasma within weeks, it is evident that, despite daily pill intake, the treatment is unable to clear the infection from the body. Furthermore, as cART drugs exhibit a much lower concentration in key HIV residual tissues, such as the brain and lymph nodes, there is a rationale for the development of drugs with enhanced tissue penetration. In addition, the treatment, with combinations of multiple different antiviral drugs that display different pharmacokinetic profiles, requires a strict dosing regimen to avoid the emergence of drug-resistant viral strains. An intriguing opportunity lies within the development of long-acting, synthetic scaffolds for delivering cART. These scaffolds can be designed with the goal to reduce the frequency of dosing and furthermore, hold the possibility of potential targeting to key HIV residual sites. Moreover, the synthesis of combinations of therapy as one molecule could unify the pharmacokinetic profiles of different antiviral drugs, thereby eliminating the consequences of sub-therapeutic concentrations. This review discusses the recent progress in the development of long-acting and tissue-targeted therapies against HIV for the delivery of direct antivirals, and examines how such developments fit in the context of exploring HIV cure strategies.<\/jats:p>","DOI":"10.3390\/v12040412","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T05:59:47Z","timestamp":1586325587000},"page":"412","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0681-3611","authenticated-orcid":false,"given":"Anna","family":"Halling Folkmar Andersen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"ref_1","unstructured":"UNAIDS (2020, January 13). Global HIV Statistics-Fact Sheet; UNAIDS 2019. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1146\/annurev.med.53.082901.104024","article-title":"The Challenge of Viral Reservoirs in HIV-1 Infection","volume":"53","author":"Blankson","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Henrich, T.J., Hatano, H., Bacon, O., Hogan, L.E., Rutishauser, R., Hill, A., Kearney, M.F., Anderson, E.M., Buchbinder, S.P., and Cohen, S.E. (2017). HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002417"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Fryer","year":"2016","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"Shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00280-004-0766-5","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates","volume":"54","author":"Berg","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/17425247.2019.1583206","article-title":"Approaches for CNS delivery of drugs\u2013nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment","volume":"16","author":"Gupta","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/1061186X.2017.1374389","article-title":"Nanocarriers for brain specific delivery of anti-retro viral drugs: Challenges and achievements","volume":"26","author":"Varghese","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"15109","DOI":"10.1073\/pnas.96.26.15109","article-title":"HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression","volume":"96","author":"Davey","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/clpt.1992.79","article-title":"Clinical pharmacokinetics of 3\u2032-azido--3\u2032--deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3\u2032-amino-3\u2032-deoxythymidine","volume":"51","author":"Stagg","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0169-409X(99)00026-5","article-title":"Involvement of multiple transporters in the oral absorption of nucleoside analogues","volume":"39","author":"Balimane","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1128\/AAC.44.8.2149-2153.2000","article-title":"Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis","volume":"44","author":"Grasela","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of lamivudine","volume":"36","author":"Johnson","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s002280050476","article-title":"The pharmacokinetics of lamivudine in patients with impaired hepatic function","volume":"54","author":"Johnson","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1128\/AAC.44.8.2061-2067.2000","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults","volume":"44","author":"McDowell","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200645110-00005","article-title":"Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment","volume":"45","author":"Kearney","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.00005-16","article-title":"Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment","volume":"60","author":"Custodio","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/105980","article-title":"Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan adults","volume":"2012","author":"Lamorde","year":"2012","journal-title":"AIDS Res. Treat."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/FTD.0b013e3181ad74a4","article-title":"Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in Southern Chinese","volume":"31","author":"To","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","article-title":"The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals","volume":"14","author":"Veldkamp","year":"2000","journal-title":"AIDS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1046\/j.1365-2125.2002.01657.x","article-title":"Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals","volume":"54","author":"Huitema","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1086\/322519","article-title":"Pharmacokinetic Interactions of Nevirapine and Methadone and Guidelines for Use of Nevirapine to Treat Injection Drug Users","volume":"33","author":"Clarke","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.clinthera.2011.08.003","article-title":"Bioavailability of Extended-Release Nevirapine 400 and 300 mg in HIV-1: A Multicenter, Open-Label Study","volume":"33","author":"Battegay","year":"2011","journal-title":"Clin. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/15284336.2017.1386811","article-title":"Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-na\u00efve patients with HIV-1 infection","volume":"18","author":"Yong","year":"2017","journal-title":"HIV Clin. Trials"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinthera.2010.02.013","article-title":"Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: An open-label, multiple-dose, controlled Phase I study in adults","volume":"32","author":"Kakuda","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_29","first-page":"46","article-title":"Oral liquid formulation of etravirine for enhanced bioavailability","volume":"6","author":"John","year":"2014","journal-title":"J. Bioequivalence Bioavailab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/jcph.107","article-title":"Impact of food and different meal types on the pharmacokinetics of rilpivirine","volume":"53","author":"Crauwels","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0009-9236(03)00006-7","article-title":"Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors","volume":"73","author":"Washington","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/AAC.47.1.350-359.2003","article-title":"Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients","volume":"47","author":"Hsu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.42.2.332","article-title":"Single-dose pharmacokinetics of indinavir and the effect of food","volume":"42","author":"Yeh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/0091270006292164","article-title":"Pharmacokinetics of nelfinavir in subjects with hepatic impairment","volume":"46","author":"Damle","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000000135","article-title":"The pharmacokinetics and acceptability of lopinavir\/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children","volume":"66","author":"Musiime","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/AAC.44.4.821-826.2000","article-title":"Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function","volume":"44","author":"Veronese","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3851\/IMP2913","article-title":"A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir\/cobicistat fixed-dose combination tablet versus administration as separate agents","volume":"20","author":"Sevinsky","year":"2015","journal-title":"Antivir. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1310\/RRX7-49ME-27V7-MWWV","article-title":"Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers","volume":"5","author":"MacGregor","year":"2004","journal-title":"HIV Clin. Trials"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0091270006298603","article-title":"The effect of different meal types on the pharmacokinetics of darunavir (TMC114)\/ritonavir in HIV-negative healthy volunteers","volume":"47","author":"Sekar","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","article-title":"Clinical pharmacokinetics of darunavir","volume":"46","author":"Rittweger","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/088922202760072294","article-title":"The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults","volume":"18","author":"Kilby","year":"2002","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2008.03137.x","article-title":"Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects","volume":"65","author":"Abel","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1128\/AAC.05739-11","article-title":"Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir","volume":"56","author":"Song","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00498254.2014.942409","article-title":"The comparative disposition and metabolism of dolutegravir, a potent HIV-1 integrase inhibitor, in mice, rats, and monkeys","volume":"45","author":"Moss","year":"2015","journal-title":"Xenobiotica"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/clpt.2008.168","article-title":"Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure","volume":"85","author":"Mathias","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_46","unstructured":"(2019, September 05). Assessment Report of Vitekta, EMA\/701401\/2013, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vitekta."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/AAC.01194-08","article-title":"Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics","volume":"53","author":"Iwamoto","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults","volume":"75","author":"Gallant","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejpb.2018.04.014","article-title":"Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy","volume":"138","author":"Gao","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0250-474X.22955","article-title":"Antiretrovirals: Need for an effective drug delivery","volume":"68","author":"Devi","year":"2006","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1002\/jps.23698","article-title":"Solubility profiling of HIV protease inhibitors in human intestinal fluids","volume":"102","author":"Wuyts","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1517\/17425255.2014.925879","article-title":"The role of formulation on the pharmacokinetics of antiretroviral drugs","volume":"10","author":"Bastiaans","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_53","first-page":"27","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"2013","author":"Amin","year":"2013","journal-title":"Drug Target. Insights"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/bm700827h","article-title":"Pharmacokinetics of saquinavir after intravenous and oral dosing of Saquinavir: Hydroxybutenyl-\u03b2-cyclodextrin formulations","volume":"9","author":"Buchanan","year":"2008","journal-title":"Biomacromolecules"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","article-title":"The physiology of the lymphatic system","volume":"50","author":"Swartz","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.addr.2007.09.007","article-title":"Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update","volume":"60","author":"Trevaskis","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.addr.2011.05.019","article-title":"Intestinal lymphatic transport for drug delivery","volume":"63","author":"Wang","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40262-014-0148-z","article-title":"Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: Implications for HIV prevention","volume":"53","author":"Trezza","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.0800050105","article-title":"Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy","volume":"105","author":"Palmer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1128\/JVI.02139-15","article-title":"Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy","volume":"90","author":"Kearney","year":"2016","journal-title":"J. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.addr.2009.11.021","article-title":"Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs","volume":"62","author":"Gunaseelan","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_63","first-page":"545","article-title":"Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: Clinical significance and potential impact on treatment and eradication of HIV\/AIDS","volume":"11","author":"Shao","year":"2016","journal-title":"Futur. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae-The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Granai","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.acra.2005.08.024","article-title":"Delivery of liposomal doxorubicin (Doxil) in a breast cancer tumor model: Investigation of potential enhancement by pulsed-high intensity focused ultrasound exposure","volume":"13","author":"Frenkel","year":"2006","journal-title":"Acad. Radiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4155\/fmc.15.57","article-title":"Gold nanoparticles to improve HIV drug delivery","volume":"7","author":"Garrido","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejpb.2018.06.002","article-title":"Nanotechnology approaches to eradicating HIV reservoirs","volume":"138","author":"Cao","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1477-3155-9-38","article-title":"Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins","volume":"9","author":"Lara","year":"2011","journal-title":"J. Nanobiotechnology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s13346-013-0134-2","article-title":"Liposomes as nanocarriers for anti-HIV therapy","volume":"3","author":"Chopra","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/jps.23773","article-title":"Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems","volume":"103","author":"Kraft","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.addr.2009.03.009","article-title":"Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy","volume":"61","author":"Aggarwal","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals-Special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"Gohla","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.addr.2016.02.003","article-title":"Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy","volume":"103","author":"Owen","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/HIV.S97920","article-title":"Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: Evidence to date","volume":"8","author":"Whitfield","year":"2016","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_79","unstructured":"(2019, August 22). ViiV Healthcare submits New Drug Application to US FDA ViiV Healthcare. Available online: https:\/\/www.viivhealthcare.com\/en-gb\/media\/press-releases\/2019\/april\/viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv\/."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41591-019-0560-x","article-title":"A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model","volume":"25","author":"Yant","year":"2019","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adhm.201500344","article-title":"Self-Immolative Linkers Literally Bridge Disulfide Chemistry and the Realm of Thiol-Free Drugs","volume":"4","author":"Riber","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/acsmacrolett.8b00179","article-title":"Long-Acting, Potent Delivery of Combination Antiretroviral Therapy","volume":"7","author":"Andersen","year":"2018","journal-title":"ACS Macro Lett."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1021\/acs.molpharmaceut.6b00156","article-title":"Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1","volume":"13","author":"Danial","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/adhm.201500841","article-title":"Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity","volume":"5","author":"Hinton","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1039\/C4CC04280H","article-title":"Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs","volume":"50","author":"Kock","year":"2014","journal-title":"Chem. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1039\/C5SC03257A","article-title":"HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat","volume":"7","author":"Zuwala","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acsmacrolett.6b00544","article-title":"Albumin-Polymer-Drug Conjugates: Long Circulating, High Payload Drug Delivery Vehicles","volume":"5","author":"Smith","year":"2016","journal-title":"ACS Macro Lett."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1128\/JVI.75.19.9037-9043.2001","article-title":"Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines","volume":"75","author":"Singh","year":"2001","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/10717544.2010.536272","article-title":"Poly (HEMA-Zidovudine) conjugate: A macromolecular pro-drug for improvement in the biopharmaceutical properties of the drug","volume":"18","author":"Neeraj","year":"2011","journal-title":"Drug Deliv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1700748","DOI":"10.1002\/adhm.201700748","article-title":"Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses","volume":"6","author":"Schandock","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2174\/1381612820666141014125213","article-title":"A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma","volume":"21","author":"Li","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2018.12.016","article-title":"Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs","volume":"294","author":"Frich","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/QAD.0000000000000971","article-title":"Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: Cocktail therapeutic strategy for antiviral therapy","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e01475","DOI":"10.1128\/AAC.01475-16","article-title":"An Enhanced Emtricitabine-Loaded Long-Acting Nanoformulation for Prevention or Treatment of HIV Infection","volume":"61","author":"Mandal","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2018.12.027","article-title":"Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission","volume":"294","author":"Mandal","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001349","article-title":"Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission","volume":"31","author":"Mandal","year":"2017","journal-title":"AIDS"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/jac\/dkq318","article-title":"Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice","volume":"65","author":"Destache","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1128\/JVI.01557-14","article-title":"Endosomal Trafficking of Nanoformulated Antiretroviral Therapy Facilitates Drug Particle Carriage and HIV Clearance","volume":"88","author":"Guo","year":"2014","journal-title":"J. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/nnm.12.214","article-title":"Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients","volume":"8","author":"Williams","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","article-title":"Long-acting slow effective release antiretroviral therapy","volume":"14","author":"Edagwa","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2174\/0929867321666140826114135","article-title":"Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies","volume":"21","author":"Edagwa","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR Treatments Eliminate HIV-1 in a Subset of Infected Humanized Mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: Strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: Opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","article-title":"Mechanistic determinants of biotherapeutics absorption following SC administration","volume":"14","author":"Richter","year":"2012","journal-title":"AAPS J."},{"key":"ref_110","first-page":"155","article-title":"Optimization of Lipid Y Indinavir Complexes for Localization in Lymphoid Tissues of HIV-Infected Macaques","volume":"42","author":"Kinman","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00126334-200312010-00005","article-title":"Lipid-Drug Association Enhanced HIV-1 Protease Inhibitor Indinavir Localization in Lymphoid Tissues and Viral Load Reduction: A Proof of Concept Study in HIV-2287-Infected Macaques","volume":"34","author":"Kinman","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"E2512","DOI":"10.1073\/pnas.1406554111","article-title":"Anti-HIV drug particles may overcome lymphatic drug insufficiency and associated HIV persistence","volume":"111","author":"Freeling","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/aid.2014.0210","article-title":"Anti-HIV Drug-Combination Nanoparticles Enhance Plasma Drug Exposure Duration as Well as Triple-Drug Combination Levels in Cells Within Lymph Nodes and Blood in Primates","volume":"31","author":"Freeling","year":"2015","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/QAD.0000000000001405","article-title":"Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma","volume":"31","author":"Kraft","year":"2017","journal-title":"AIDS"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/1061186X.2018.1433681","article-title":"Indocyanine green nanoparticles undergo selective lymphatic uptake, distribution and retention and enable detailed mapping of lymph vessels, nodes and abnormalities","volume":"26","author":"Kraft","year":"2018","journal-title":"J. Drug Target."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"8255","DOI":"10.1039\/C6NR00506C","article-title":"Human immune cell targeting of protein nanoparticles-caveospheres","volume":"8","author":"Glass","year":"2016","journal-title":"Nanoscale"},{"key":"ref_118","first-page":"2847","article-title":"Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD + immune cells","volume":"8","author":"Yang","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejpb.2014.11.021","article-title":"Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs-Modern Trojan horses to combat HIV","volume":"89","author":"Ramana","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Kovochich, M., Marsden, M.D., and Zack, J.A. (2011). Activation of Latent HIV Using Drug-Loaded Nanoparticles. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018270"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/QAI.0b013e3182653c1f","article-title":"Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles","volume":"61","author":"Endsley","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-012-9329-6","article-title":"Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells","volume":"14","author":"Endsley","year":"2012","journal-title":"AAPS J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"8164","DOI":"10.1128\/jvi.69.12.8164-8168.1995","article-title":"Role of CD4 endocytosis in human immunodeficiency virus infection","volume":"69","author":"Clapham","year":"1995","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1084\/jem.173.3.575","article-title":"Differential endocytosis of CD4 in lymphocytic and nonlymphocytic cells","volume":"173","author":"Armes","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/QAD.0b013e32830efd96","article-title":"N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery","volume":"22","author":"Pollock","year":"2008","journal-title":"AIDS"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature21710","article-title":"CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses","volume":"543","author":"Descours","year":"2017","journal-title":"Nature"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.celrep.2020.01.071","article-title":"CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency","volume":"30","author":"Darcis","year":"2020","journal-title":"Cell Rep."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1038\/s41586-018-0494-3","article-title":"The role of CD32 during HIV-1 infection","volume":"561","author":"Bertagnolli","year":"2018","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1038\/s41586-018-0495-2","article-title":"Evidence that CD32a does not mark the HIV-1 latent reservoir","volume":"561","author":"Osuna","year":"2018","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1038\/s41586-018-0493-4","article-title":"Conflicting evidence for HIV enrichment in CD32 + CD4 T cells","volume":"561","author":"Anderson","year":"2018","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"eaar6759","DOI":"10.1126\/scitranslmed.aar6759","article-title":"CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells","volume":"10","author":"Spivak","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3389\/fimmu.2018.00928","article-title":"CD32-expressing CD4 T cells are phenotypically diverse and can contain proviral HIV DNA","volume":"9","author":"Martin","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/infdis\/jiz572","article-title":"Circulating CD30+ CD4+ T Cells Increase Prior to HIV Rebound Following Analytical Antiretroviral Treatment Interruption","volume":"221","author":"Prator","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/bloodadvances.2018024364","article-title":"Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma","volume":"2","author":"Wang","year":"2018","journal-title":"Blood Adv."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/COH.0000000000000279","article-title":"Shocking HIV out of hiding: Where are we with clinical trials of latency reversing agents?","volume":"11","author":"Rasmussen","year":"2016","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2147\/IJN.S76517","article-title":"Sustained-release nanoART formulation for the treatment of neuroAIDS","volume":"10","author":"Jayant","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s11671-015-1112-z","article-title":"PLGA-PEG Nanoparticles Coated with Anti-CD45RO and Loaded with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit Viral Spread","volume":"10","author":"Tang","year":"2015","journal-title":"Nanoscale Res. Lett."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering crispr: A review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/412\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:16:23Z","timestamp":1760174183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/12\/4\/412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":138,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4]]}},"alternative-id":["v12040412"],"URL":"https:\/\/doi.org\/10.3390\/v12040412","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]}}}